Open AccessA case series of serious and unexpected adverse drug reactions under treatment with cariprazine
Author(s) -
Heck Johannes,
Seifert Johanna,
Stichtenoth Dirk O.,
Schroeder Christoph,
Groh Adrian,
Szycik Gregor R.,
Degner Detlef,
Adamovic Ivana,
Schneider Michael,
Glocker Catherine,
Rüther Eckart,
Bleich Stefan,
Grohmann Renate,
Toto Sermin
Publication year - 2021
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.4084
Subject(s) - medicine , drug reaction , intensive care medicine , pharmacotherapy , drug , adverse drug reaction , adverse effect , antipsychotic drug , pharmacology , antipsychotic , psychiatry , schizophrenia (object oriented programming)
Reporting of new or unexpected adverse drug reactions of medicines that are subject to additional monitoring (“black triangle” label), such as the antipsychotic drug cariprazine, is of paramount importance to improve pharmacotherapy safety.